NEW YORK (AP) - Pfizer will acquire Anacor Pharmaceuticals Inc. in a deal valued at about $5.2 billion.
Anacor's topical treatment for eczema, called crisaborole, is currently under review by the Food and Drug Administration. If approved, Pfizer said it believes peak year sales could reach or exceed $2 billion.
Pfizer buying Anacor Pharmaceuticals in $5.2B deal
Aucun commentaire:
Enregistrer un commentaire